AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results
May 4, 2016 6:39 AM EDT
Raymond James downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Outperform to Market Perform and removed its price target (prior $55.00).
For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.
Shares of AMAG Pharmaceuticals closed at $22.03 yesterday.
...
More
May 3, 2016 7:07 AM EDT
AMAG Pharma (NASDAQ: AMAG) reported Q1 EPS of $0.94, $0.17 worse than the analyst estimate of $1.11. Revenue for the quarter came in at $117.6 million versus the consensus estimate of $124.83 million.
We are off to a strong start in 2016, achieving goals on our next-generation program for Makena, including the commercial launch of our new single-dose, preservative-free formulation, as well as solidifying an important new strategic relationship to further expand access to FDA-approved Makena, said William Heiden, AMAGs chief... More
